Abstract
The most accepted and least biased manner to demonstrate clinical benefit for any new treatment is to show that it conveys a survival advantage in a well-designed phase III, randomized clinical trial. However, in selected cases, an exception can be made to this sound rule. This review aims at elucidating one such example. In particular, I intend to show that when an individualized form of immunotherapy like idiotypic vaccination, which by definition is completely inactive against any tumor cells, is applied to cancer patients with indolent follicular lymphoma, a carefully crafted phase II clinical trial may be able to demonstrate clinical benefit better and more rapidly than a phase III alternative. This consideration might be rather important over the next two to three years, since the results of as many as three ongoing phase III clinical trials on idiotype vaccines are expected to be unveiled within this time frame, following the release of conclusive data of our phase II clinical trial, which is imminent.
Keywords: immunoglobulin, cell-mediated cytotoxicity (ADCC), T lymphocytes (CTLs), chemotherapy, phase II clinical trials, transfectants
Reviews on Recent Clinical Trials
Title: Clinical Benefit of Idiotype Vaccines: Too Many Trials for a Clever Demonstration?
Volume: 1 Issue: 1
Author(s): Maurizio Bendandi
Affiliation:
Keywords: immunoglobulin, cell-mediated cytotoxicity (ADCC), T lymphocytes (CTLs), chemotherapy, phase II clinical trials, transfectants
Abstract: The most accepted and least biased manner to demonstrate clinical benefit for any new treatment is to show that it conveys a survival advantage in a well-designed phase III, randomized clinical trial. However, in selected cases, an exception can be made to this sound rule. This review aims at elucidating one such example. In particular, I intend to show that when an individualized form of immunotherapy like idiotypic vaccination, which by definition is completely inactive against any tumor cells, is applied to cancer patients with indolent follicular lymphoma, a carefully crafted phase II clinical trial may be able to demonstrate clinical benefit better and more rapidly than a phase III alternative. This consideration might be rather important over the next two to three years, since the results of as many as three ongoing phase III clinical trials on idiotype vaccines are expected to be unveiled within this time frame, following the release of conclusive data of our phase II clinical trial, which is imminent.
Export Options
About this article
Cite this article as:
Bendandi Maurizio, Clinical Benefit of Idiotype Vaccines: Too Many Trials for a Clever Demonstration?, Reviews on Recent Clinical Trials 2006; 1 (1) . https://dx.doi.org/10.2174/157488706775246120
DOI https://dx.doi.org/10.2174/157488706775246120 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ruthenium Complexes as Anticancer Agents
Current Medicinal Chemistry Molecular Pathways Linking Inflammation and Cancer
Current Molecular Medicine Discovery of Modulators of Protein-Protein Interactions: Current Approaches and Limitations
Current Topics in Medicinal Chemistry Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials The p53 Pathway Encounters the MicroRNA World
Current Genomics A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Regulation of Death and Growth Signals at the Plasma Membrane by Sphingomyelin Synthesis: Implications for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Emerging Breast Cancer Biomarkers
Current Cancer Therapy Reviews The Role of the Transcription Factor E2F1 in Hepatocellular Carcinoma
Current Drug Delivery Weight Optimized Neural Network Using Metaheuristics for the Classification of Large Cell Carcinoma and Adenocarcinoma from Lung Imaging
Current Signal Transduction Therapy MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer
Current Cancer Drug Targets Radioimmunotherapy of Metastatic Prostate Cancer with <sup>177</sup>Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody
Current Radiopharmaceuticals Development and biological studies of <sup>177</sup>Lu-DOTA-rituximab for the treatment of Non-Hodgkin’s lymphoma
Current Radiopharmaceuticals Repertoire of Gluten Peptides Active in Celiac Disease Patients: Perspectives For Translational Therapeutic Applications
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Karyotypic Complexity and Chromosomal Instability of Cancer Cells
Current Drug Targets Concentration-Dependent Bimodal Effect of Specific 18 kDa Translocator Protein (TSPO) Ligands on Cell Death Processes Induced by Ammonium Chloride: Potential Implications for Neuropathological Effects Due to Hyperammonemia
CNS & Neurological Disorders - Drug Targets Toll-Like Receptors in Alzheimer's Disease: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets Interaction Between Arsenic Trioxide and Human Primary Cells: Emphasis on Human Cells of Myeloid Origin
Inflammation & Allergy - Drug Targets (Discontinued) CD4+ T-cell Count may not be a Useful Strategy to Monitor Antiretroviral Therapy Response in HTLV-1/HIV Co-infected Patients
Current HIV Research Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy
CNS & Neurological Disorders - Drug Targets